References
[1]. Ludwig, J., and Weinstein, J. (2005). Biomarkers in
cancer staging, prognosis and treatment selection.
Nature Rev. Cancer, 5, 845-856.
[2]. Catalona, W. (1996). Clinical utility of measurements
of free and total prostate-specific antigen (PSA): a review.
Prostate, 7, 64-69.
[3]. Ushaa Eswaran, M. Madhavilatha, and
Madhusudhana Rao Ganji. (2006). A Proposal for Design
of Hybrid Multi-Functional Implantable Biochip Using Bio-
Intelligent Expert System' The 2006 International
Conference on Artificial Intelligence (ICAI'06) June 26-29,
Las Vegas, USA.
[4]. Ushaa Eswaran, Madhusudhan Rao Ganji,
Jayashankar, T.S., and Lekha Suresh, (2006). 'Design of
implantable VLSI bio-chip', National conference on
Advanced Communication Technologies [ACT-06], 8-9
December.
[5]. Ushaa Eswaran, and M. Madhavilatha, (2009).
“ Disease Detection Using Pattern Recognition
Techniques” National Conference on 'Emerging Trends in
Information Communication Technology' (ETICT-08) held
th th in GITAM University, India during 19 & 20 December and
is published in GITAM Journal of Information
Communication Technology, Vol. 2, January - July 2009
Number - 1 (ISSN 0974-4622) pp.34-37.
[6]. Ushaa Eswaran, Madhusudhana Rao, and M.S.
Thakur (2004). 'Microprocessor Based Biosensors for
Determination of Toxins and Pathogens in Restricted Areas
of Human Intervention' IC AI'04 IEEE sponsored
International Conference on Artificial Intelligence held in
Las Vegas, Nevada, USA during 21–24 June.
[7]. Beckett, M., Cazares, L., Vlahou, A., Schellhammer, P.,
and Wright, G. (1995). Prostate-specific membrane
antigen levels in sera from healthy men and patients with
benign prostate hyperplasia or prostate cancer. Clin.
Cancer Res., 5, 4034-4040.
[8]. Henderson, C., and Patek, A. (1998). The relationship
between prognostic and predictive factors in the
management of breast cancer. Breast Cancer Res.
Treat., 52, 261-288.
[9]. Dandachi, N., Dietze, O., and Hauser-Kronberger, C.
(2002). Chromogenic in situ hybridization: a novel
approach to a practical and sensitive method for the
detection of HER2 oncogene in archival human breast
carcinoma. Lab. Invest., 82, 1007–1014.
[10]. Molina, R., Auge, J., Escudero, J., Marrades, R.,
Vinolas, N., Carcereny, E., Ramirez, J., and Filella, X.
Mucins. (2008). CA 125, CA 19.9, CA 15.3 and TAG-72.3
as tumor markers in patients with lung cancer:
comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor
Biol., 29, 371-380.
[11]. Landman, J., Chang, Y., Kavaler, E., Droller, M., and
Liu, B. (1998). Sensitivity and specificity of NMP-22,
telomerase, and BTA in the detection of human bladder
cancer. Urology 1998, 52, 398-402.
[12]. Prow, T.W., Rose, W.A., Wang, N., Reece, L.M., Lvov,
Y., and Leary, J.F. (2005). "Biosensor-Controlled Gene Therapy/Drug Delivery with Nanoparticles for
Nanomedicine" Proc. of SPIE 5692: 199-208.
[13]. Prow, T.W., Smith, J.N., Grebe, R., Salazar, J.H., Wang,
N., Kotov, N., Lutty, G., and Leary, J.F. (2006).
"Construction, Gene Delivery, and Expression of DNA
Tethered Nanoparticles" Molecular Vision 12: 606-615.
[14]. Prow, T.W., Grebe, R., Merges, C., Smith, J.N.,
McLeod, D.S., Leary, J.F., Gerard A., and Lutty, G.A.
(2006). "Novel therapeutic gene regulation by genetic
biosensor tethered to magnetic nanoparticles for the
detection and treatment of retinopathy of prematurity"
Molecular Vision 12: 616-625.
[15]. www.nanohub.org
[16]. Seeman, (2005). From genes to machines: DNA
Nanomechanical devices. TRENDS in Biochemical
Sciences 30.
